LIXT
Lixte Biotechnology Holdings, Inc.
Biotechnology
Market Cap$25M
5Y Perf.-91.7%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
LIXT vs IQV
Revenue, margins, valuation, and 5-year total return — side by side.
IQV
IQVIA Holdings Inc.
Medical - Diagnostics & Research
Market Cap$29.95B
5Y Perf.+18.0%
LIXT vs IQV — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | LIXT | IQV |
|---|---|---|
| Industry | Biotechnology | Medical - Diagnostics & Research |
| Market Cap | $25M | $29.95B |
| Revenue (TTM) | $0.00 | $16.63B |
| Net Income (TTM) | $-4M | $1.39B |
| Gross Margin | — | 26.1% |
| Operating Margin | — | 13.9% |
| Forward P/E | — | 13.9x |
| Total Debt | $0.00 | $16.17B |
| Cash & Equiv. | $1M | $1.98B |
LIXT vs IQV — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
LIXT
IQV
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Lixte Biotechnology… (LIXT) | 100 | 8.3 | -91.7% |
| IQVIA Holdings Inc. (IQV) | 100 | 118.0 | +18.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LIXT vs IQV
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: LIXT leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. IQVIA Holdings Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
LIXT
Lixte Biotechnology Holdings, Inc.
The Income Pick
LIXT carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 1.09
- EPS growth 40.2%
- Lower volatility, beta 1.09, current ratio 3.26x
Best for: income & stability and growth exposure
IQV
IQVIA Holdings Inc.
The Long-Run Compounder
IQV is the clearest fit if your priority is long-term compounding.
- 167.5% 10Y total return vs LIXT's -38.9%
- 8.3% margin vs LIXT's 0.6%
- 4.7% ROA vs LIXT's -178.1%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | LIXT | 66.2% revenue growth vs IQV's 5.9% |
| Quality / Margins | IQV | 8.3% margin vs LIXT's 0.6% |
| Stability / Safety | LIXT | Beta 1.09 vs IQV's 1.33 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | LIXT | +272.9% vs IQV's +20.7% |
| Efficiency (ROA) | IQV | 4.7% ROA vs LIXT's -178.1% |
LIXT vs IQV — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
LIXT vs IQV — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLIQVLAGGINGLIXT
LIXTLixte Biotechnology H…
1leads
IQVIQVIA Holdings Inc.
3leads
6 Total Categories
CATEGORYLEADERvs LIXTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
LIXT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
IQV5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
IQV4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
IQV1/1
Income & Cash Flow (Last 12 Months)
LIXT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
IQV and LIXT operate at a comparable scale, with $16.6B and $0 in trailing revenue.
| Metric | LIXTLixte Biotechnolo… | IQVIQVIA Holdings In… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $16.6B |
| EBITDAEarnings before interest/tax | -$3M | $3.5B |
| Net IncomeAfter-tax profit | -$4M | $1.4B |
| Free Cash FlowCash after capex | -$3M | $2.7B |
| Gross MarginGross profit ÷ Revenue | — | +26.1% |
| Operating MarginEBIT ÷ Revenue | — | +13.9% |
| Net MarginNet income ÷ Revenue | — | +8.3% |
| FCF MarginFCF ÷ Revenue | — | +16.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +8.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +25.0% | +15.0% |
LIXT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — LIXT and IQV each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | LIXTLixte Biotechnolo… | IQVIQVIA Holdings In… |
|---|---|---|
| Market CapShares × price | $25M | $29.9B |
| Enterprise ValueMkt cap + debt − cash | $24M | $44.1B |
| Trailing P/EPrice ÷ TTM EPS | -2.77x | 22.51x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 13.89x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.56x |
| EV / EBITDAEnterprise value multiple | — | 12.87x |
| Price / SalesMarket cap ÷ Revenue | — | 1.84x |
| Price / BookPrice ÷ Book value/share | 11.96x | 4.62x |
| Price / FCFMarket cap ÷ FCF | — | 14.60x |
Evenly matched — LIXT and IQV each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
IQV leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
IQV delivers a 22.1% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $-2 for LIXT. On the Piotroski fundamental quality scale (0–9), IQV scores 4/9 vs LIXT's 1/9, reflecting mixed financial health.
| Metric | LIXTLixte Biotechnolo… | IQVIQVIA Holdings In… |
|---|---|---|
| ROE (TTM)Return on equity | -2.2% | +22.1% |
| ROA (TTM)Return on assets | -178.1% | +4.7% |
| ROICReturn on invested capital | — | +8.7% |
| ROCEReturn on capital employed | -148.2% | +11.0% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 |
| Debt / EquityFinancial leverage | — | 2.44x |
| Net DebtTotal debt minus cash | -$1M | $14.2B |
| Cash & Equiv.Liquid assets | $1M | $2.0B |
| Total DebtShort + long-term debt | $0 | $16.2B |
| Interest CoverageEBIT ÷ Interest expense | -419.37x | 3.10x |
IQV leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
IQV leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IQV five years ago would be worth $7,632 today (with dividends reinvested), compared to $1,560 for LIXT. Over the past 12 months, LIXT leads with a +272.9% total return vs IQV's +20.7%. The 3-year compound annual growth rate (CAGR) favors IQV at -2.4% vs LIXT's -6.6% — a key indicator of consistent wealth creation.
| Metric | LIXTLixte Biotechnolo… | IQVIQVIA Holdings In… |
|---|---|---|
| YTD ReturnYear-to-date | +14.6% | -21.7% |
| 1-Year ReturnPast 12 months | +272.9% | +20.7% |
| 3-Year ReturnCumulative with dividends | -18.5% | -7.0% |
| 5-Year ReturnCumulative with dividends | -84.4% | -23.7% |
| 10-Year ReturnCumulative with dividends | -38.9% | +167.5% |
| CAGR (3Y)Annualised 3-year return | -6.6% | -2.4% |
IQV leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — LIXT and IQV each lead in 1 of 2 comparable metrics.
Risk & Volatility
LIXT is the less volatile stock with a 1.09 beta — it tends to amplify market swings less than IQV's 1.33 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | LIXTLixte Biotechnolo… | IQVIQVIA Holdings In… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.09x | 1.33x |
| 52-Week HighHighest price in past year | $6.26 | $247.05 |
| 52-Week LowLowest price in past year | $0.64 | $134.65 |
| % of 52W HighCurrent price vs 52-week peak | +70.3% | +71.4% |
| RSI (14)Momentum oscillator 0–100 | 70.4 | 58.4 |
| Avg Volume (50D)Average daily shares traded | 38K | 1.6M |
Evenly matched — LIXT and IQV each lead in 1 of 2 comparable metrics.
Analyst Outlook
IQV leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
| Metric | LIXTLixte Biotechnolo… | IQVIQVIA Holdings In… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $225.63 |
| # AnalystsCovering analysts | — | 44 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | 2 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +4.2% |
IQV leads this category, winning 1 of 1 comparable metric.
Key Takeaway
IQV leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). LIXT leads in 1 (Income & Cash Flow). 2 tied.
Best OverallIQVIA Holdings Inc. (IQV)Leads 3 of 6 categories
Loading custom metrics...
LIXT vs IQV: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is LIXT or IQV a better buy right now?
IQVIA Holdings Inc.
(IQV) offers the better valuation at 22. 5x trailing P/E (13. 9x forward), making it the more compelling value choice. Analysts rate IQVIA Holdings Inc. (IQV) a "Buy" — based on 44 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — LIXT or IQV?
Over the past 5 years, IQVIA Holdings Inc.
(IQV) delivered a total return of -23. 7%, compared to -84. 4% for Lixte Biotechnology Holdings, Inc. (LIXT). Over 10 years, the gap is even starker: IQV returned +167. 5% versus LIXT's -38. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — LIXT or IQV?
By beta (market sensitivity over 5 years), Lixte Biotechnology Holdings, Inc.
(LIXT) is the lower-risk stock at 1. 09β versus IQVIA Holdings Inc. 's 1. 33β — meaning IQV is approximately 22% more volatile than LIXT relative to the S&P 500.
04Which is growing faster — LIXT or IQV?
On earnings-per-share growth, the picture is similar: Lixte Biotechnology Holdings, Inc.
grew EPS 40. 2% year-over-year, compared to 4. 7% for IQVIA Holdings Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — LIXT or IQV?
IQVIA Holdings Inc.
(IQV) is the more profitable company, earning 8. 3% net margin versus 0. 0% for Lixte Biotechnology Holdings, Inc. — meaning it keeps 8. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IQV leads at 14. 0% versus 0. 0% for LIXT. At the gross margin level — before operating expenses — IQV leads at 26. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — LIXT or IQV?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is LIXT or IQV better for a retirement portfolio?
For long-horizon retirement investors, Lixte Biotechnology Holdings, Inc.
(LIXT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 09)). Both have compounded well over 10 years (LIXT: -38. 9%, IQV: +167. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between LIXT and IQV?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.